We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Emergent Biosolutions (EBS) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Emergent Biosolutions (EBS - Free Report) closed the most recent trading day at $99.55, moving +1.86% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.15%. Meanwhile, the Dow lost 0.07%, and the Nasdaq, a tech-heavy index, lost 0.47%.
Heading into today, shares of the biopharmaceutical company had lost 4.5% over the past month, lagging the Medical sector's gain of 0.71% and the S&P 500's gain of 3.19% in that time.
Wall Street will be looking for positivity from EBS as it approaches its next earnings report date. The company is expected to report EPS of $2.05, up 69.42% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $451.85 million, up 44.92% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.61 per share and revenue of $1.53 billion, which would represent changes of +127.15% and +38.28%, respectively, from the prior year.
Any recent changes to analyst estimates for EBS should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.56% higher. EBS currently has a Zacks Rank of #1 (Strong Buy).
Investors should also note EBS's current valuation metrics, including its Forward P/E ratio of 14.78. This represents a discount compared to its industry's average Forward P/E of 26.35.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 174, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Emergent Biosolutions (EBS) Gains As Market Dips: What You Should Know
Emergent Biosolutions (EBS - Free Report) closed the most recent trading day at $99.55, moving +1.86% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.15%. Meanwhile, the Dow lost 0.07%, and the Nasdaq, a tech-heavy index, lost 0.47%.
Heading into today, shares of the biopharmaceutical company had lost 4.5% over the past month, lagging the Medical sector's gain of 0.71% and the S&P 500's gain of 3.19% in that time.
Wall Street will be looking for positivity from EBS as it approaches its next earnings report date. The company is expected to report EPS of $2.05, up 69.42% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $451.85 million, up 44.92% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.61 per share and revenue of $1.53 billion, which would represent changes of +127.15% and +38.28%, respectively, from the prior year.
Any recent changes to analyst estimates for EBS should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.56% higher. EBS currently has a Zacks Rank of #1 (Strong Buy).
Investors should also note EBS's current valuation metrics, including its Forward P/E ratio of 14.78. This represents a discount compared to its industry's average Forward P/E of 26.35.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 174, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.